Top news of September: Sunscreen, endocrine-disrupting chemicals, Ozempic, more

Key takeaways:

• Healio Dermatology’s article about the FDA’s lack of sunscreen approvals topped September coverage.
• A study finding endocrine-disrupting chemicals in children followed.

The FDA’s inaction approving sunscreen ingredients as well as studies about endocrine-disrupting chemicals in personal care products and Ozempic’s impact on hidradenitis suppurativa led Healio Dermatology’s most-read articles in September.

Here are the top articles from last month.

‘Clear as mud’: Why the FDA has not approved new sunscreen ingredients

Topping this month’s list is Healio’s article on the FDA’s lack of action in approving new sunscreen ingredients. The agency has not approved a new sunscreen ingredient since the 1990s, leaving consumers and clinicians wondering why. Healio spoke with multiple experts on the topic. Read more.

Endocrine-disrupting chemicals from personal care products found in young children

The use of personal care products was associated with endocrine-disrupting chemicals called phthalates in children aged as young as 4 years, according to a study. Healio spoke with Michael S. Bloom, PhD, professor in the department of global and community health at the College of Public Health at George Mason University, about these results. Read more.

Semaglutide improves hidradenitis suppurativa outcomes

A presentation from the European Academy of Dermatology and Venereology Congress showed that semaglutide (Ozempic, Novo Nordisk) was shown to reduce hidradenitis suppurativa flares in patients with obesity. Jennifer Hsiao, MD, associate professor of dermatology at Keck School of Medicine of University of Southern California, provided her Perspective. Read more.

No changes to CDC guidelines recommending children with lice do not need to leave school

As kids return to school, the CDC reminded the public that its policy regarding sending children with lice home early from school has not changed, despite media outlets reporting the opposite. Danilo Del Campo, MD, FAAD, a dermatologist at the Chicago Skin Clinic, discussed why the CDC’s advice makes sense. Read more.

Q&A: FDA must ‘do right’ by explaining delayed ban of formaldehyde in hair products

The FDA has missed its action date to address its proposed rule banning formaldehyde and formaldehyde-releasing chemicals from hair smoothing and straightening products. Chris G. Adigun, MD, FAAD, the owner and medical director of Dermatology & Laser Center of Chapel Hill, spoke with Healio on the importance of this topic. Read more.

Most patients with chronic hand eczema suffer from corticosteroid phobia

A new study found that the majority of patients with chronic hand eczema suffer from corticosteroid phobia, which negatively impacts treatment adherence. Read more.

Low-dose metformin associated with central centrifugal cicatricial alopecia improvement

Down regulation of fibrotic processes and upregulation of keratinocyte proliferation was associated with low-dose metformin in patients with central centrifugal cicatricial alopecia, according to a study. Read more.

Exosome technology delivers positive results for patients with hair loss

New results show that Elevai Labs’ exosome technology can successfully restore hair growth in combination with other hair treatments, the company announced in a press release. Read more.

Beneath the Surface: Exploring sodium’s effect on dermatologic disease

In the latest installment of Beneath the Surface, Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, James J. Leyden Professor of Clinical Investigation and professor of dermatology and epidemiology at University of Pennsylvania’s Perelman School of Medicine, discussed the possible role of sodium in dermatologic diseases with Katrina Abuabara, MD, MA, MSCE, associate professor of dermatology at University of California, San Francisco. Watch here.

Q&A: MoCRA tames the ‘wild, wild West’ of cosmetics with impending deadline

The cosmetic industry is preparing for yet another rapidly approaching deadline imposed by the Modernization of Cosmetics Registration Act of 2022. Jaclyn Bellomo, MS, MBA, director of cosmetic science and regulatory affairs at Registrar Corp, spoke with Healio on the details and implications of this deadline. Read more.